{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:55:51Z","timestamp":1780451751307,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"crossref","award":["No.2022SF-451"],"award-info":[{"award-number":["No.2022SF-451"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"crossref","award":["No.2022SF-451"],"award-info":[{"award-number":["No.2022SF-451"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.82170626"],"award-info":[{"award-number":["No.82170626"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is a lack of effective programmed cell death protein 1 (PD-1)\u2010targeted immunotherapy with good tolerability in patients with advanced hepatocellular carcinoma (HCC) and severely compromised liver function. We assessed patient outcomes after combined camrelizumab and molecular targeted therapy in a multicenter cohort study in China. The study included 99 patients with advanced HCC (58 Child-Pugh A and 41 Child-Pugh B), 84 of them received camrelizumab combined with molecular targeted therapy from January 10, 2019, to March 31, 2021. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were assessed. The median follow-up was 12.1\u00a0months. For patients with Child-Pugh B, the OS probability at 12-months, ORR and DCR were 49.7%, 31.7% and 65.9%, respectively, and the median PFS was 5.1\u00a0months [95% confidence interval (CI) 3.0\u20137.1], which were comparable with Child-Pugh A patients, although median OS was shorter in Child\u2010Pugh B patients (20.5 vs.13.4\u00a0months, <jats:italic>P<\/jats:italic>\u2009=\u20090.12). In multivariate analysis, macrovascular infiltration (MVI), but not sex, age, hepatitis B virus etiology, extrahepatic metastasis, Child-Pugh B, or AFP\u2009&gt;\u2009400\u00a0ng\/ml, was associated with 12-months OS [hazard ratio (HR) 2.970, 95% CI 1.276\u20136.917, <jats:italic>P<\/jats:italic>\u2009=\u20090.012] and ORR (HR 2.906, 95% CI 1.18\u20137.16, <jats:italic>P<\/jats:italic>\u2009=\u20090.020). Grade 3\/4 immune-related AEs occurred in 26.8% of Child-Pugh B patients, including one potentially treatment-related death. In both groups, the most common AEs were immune thrombocytopenia and hepatotoxicity. Camrelizumab combined with targeted therapy showed favorable effectiveness and tolerability with manageable toxicities in Chinese HCC patients, regardless of Child-Pugh A\/B liver function. MVI was associated with suboptimal immunotherapy response and poor prognosis.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s00262-023-03404-8","type":"journal-article","created":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T10:02:47Z","timestamp":1677319367000},"page":"2137-2149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC"],"prefix":"10.1007","volume":"72","author":[{"given":"Ting","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangwei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-4989","authenticated-orcid":false,"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-8035","authenticated-orcid":false,"given":"Fanpu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,25]]},"reference":[{"key":"3404_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"3404_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16:589\u2013604","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3404_CR3","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/cac2.12195","volume":"41","author":"D Jiang","year":"2021","unstructured":"Jiang D, Zhang L, Liu W et al (2021) Trends in cancer mortality in China from 2004 to 2018: a nationwide longitudinal study. Cancer Commun (Lond) 41:1024\u20131036","journal-title":"Cancer Commun (Lond)"},{"key":"3404_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115\u2013132","journal-title":"CA Cancer J Clin"},{"key":"3404_CR5","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","volume":"385","author":"C Allemani","year":"2015","unstructured":"Allemani C, Weir HK, Carreira H et al (2015) Global surveillance of cancer survival 1995\u20132009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385:977\u20131010","journal-title":"Lancet"},{"key":"3404_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau T, Kang YK, Kim TY et al (2020) Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 Randomized Clinical Trial. JAMA Oncol 6:e204564","journal-title":"JAMA Oncol"},{"key":"3404_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo BY, Merle P et al (2020) Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 38:193\u2013202","journal-title":"J Clin Oncol"},{"key":"3404_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jhep.2019.05.014","volume":"71","author":"T Yau","year":"2019","unstructured":"Yau T, Hsu C, Kim TY et al (2019) Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol 71:543\u2013552","journal-title":"J Hepatol"},{"key":"3404_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S et al (2021) Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res 27:1003\u20131011","journal-title":"Clin Cancer Res"},{"key":"3404_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, Ren Z, Meng Z et al (2020) Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 21:571\u2013580","journal-title":"Lancet Oncol"},{"key":"3404_CR11","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/apt.15245","volume":"49","author":"B Scheiner","year":"2019","unstructured":"Scheiner B, Kirstein MM, Hucke F et al (2019) Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther 49:1323\u20131333","journal-title":"Aliment Pharmacol Ther"},{"key":"3404_CR12","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","volume":"75","author":"M Kudo","year":"2021","unstructured":"Kudo M, Matilla A, Santoro A et al (2021) CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and child-pugh B cirrhosis. J Hepatol 75:600\u2013609","journal-title":"J Hepatol"},{"key":"3404_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng A-L, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317\u2013370","journal-title":"Hepatol Int"},{"key":"3404_CR14","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet JM, Lencioni R (2020) mRECIST for HCC: performance and novel refinements. J Hepatol 72:288\u2013306","journal-title":"J Hepatol"},{"key":"3404_CR15","doi-asserted-by":"publisher","first-page":"eaan5616","DOI":"10.1126\/scitranslmed.aan5616","volume":"9","author":"M Pinter","year":"2017","unstructured":"Pinter M, Jain RK (2017) Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy. Sci Transl Med 9:eaan5616","journal-title":"Sci Transl Med"},{"key":"3404_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26:605\u2013622","journal-title":"Cancer Cell"},{"key":"3404_CR17","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.2147\/CMAR.S304820","volume":"13","author":"F Wei","year":"2021","unstructured":"Wei F, Huang Q, He J, Luo L, Zeng Y (2021) Lenvatinib plus camrelizumab versus lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma: a short-term prognostic study. Cancer Manag Res 13:4233\u20134240","journal-title":"Cancer Manag Res"},{"key":"3404_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.684867","volume":"11","author":"C Han","year":"2021","unstructured":"Han C, Ye S, Hu C et al (2021) Clinical activity and safety of penpulimab (anti-PD-1) with anlotinib as first-line therapy for unresectable hepatocellular carcinoma: an open-Label, multicenter, phase Ib\/II trial (AK105-203). Front Oncol 11:684867","journal-title":"Front Oncol"},{"key":"3404_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1572-0241.2006.00364.x","volume":"101","author":"MC Cantarini","year":"2006","unstructured":"Cantarini MC, Trevisani F, Morselli-Labate AM et al (2006) Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol 101:91\u201398","journal-title":"Am J Gastroenterol"},{"key":"3404_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112184","volume":"9","author":"DH Sinn","year":"2014","unstructured":"Sinn DH, Gwak GY, Cho J, Paik SW, Yoo BC (2014) Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort. PLoS ONE 9:e112184","journal-title":"PLoS ONE"},{"key":"3404_CR21","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19:940\u2013952","journal-title":"Lancet Oncol"},{"key":"3404_CR22","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389:2492\u20132502","journal-title":"Lancet"},{"key":"3404_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-020-00886-2","volume":"13","author":"F Wang","year":"2020","unstructured":"Wang F, Qin S, Sun X et al (2020) Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol 13:47","journal-title":"J Hematol Oncol"},{"key":"3404_CR24","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1016\/j.apsb.2021.10.003","volume":"11","author":"L Shojaie","year":"2021","unstructured":"Shojaie L, Ali M, Iorga A, Dara L (2021) Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharm Sin B 11:3727\u20133739","journal-title":"Acta Pharm Sin B"},{"key":"3404_CR25","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","volume":"7","author":"X Zhang","year":"2019","unstructured":"Zhang X, Zhou Y, Chen C et al (2019) Hepatitis B virus reactivation in cancer patients with positive hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer 7:322","journal-title":"J Immunother Cancer"},{"key":"3404_CR26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jhep.2020.08.010","volume":"74","author":"CG Kim","year":"2021","unstructured":"Kim CG, Kim C, Yoon SE et al (2021) Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. J Hepatol 74:350\u2013359","journal-title":"J Hepatol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03404-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03404-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03404-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T12:04:58Z","timestamp":1686657898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03404-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,25]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["3404"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03404-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,25]]},"assertion":[{"value":"13 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author\u2019s declaration of personal interests: Mindie H. Nguyen: Grants: Gilead, Pfizer, Enanta, Vir, Glycotest, National Cancer Institute, B. K. Kee Foundation, Exact Sciences; Helio Health; Consulting or advisory board: Intercept, Gilead, Exact Sciences, Laboratory of Advanced Medicine, Bayer, Eisai, GSK, Novartis. Fanpu Ji: Speaker: Gilead Sciences, MSD and Ascletis. Consulting or advisory board: Gilead Sciences and MSD. All other authors do not have conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was carried out in accordance with the International Conference on Good Clinical Practice Standards and the Declaration of Helsinki and was approved by the Institutional Ethics Committees of The Second Affiliated Hospital of Xi\u2019an Jiaotong University (2018059; Shaanxi, China). Institutional ethics review was waived at other participating centers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All data and materials of this study are available from the corresponding author upon request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}